Myriad Genetics Inc. (MYGN) Is Climbing On Pfizer Deal

Myriad Genetics Inc. (MYGN) announced Wednesday morning that it has signed a new laboratory services agreement with Pfizer Inc. (PFE).

Myriad Genetics gapped open higher Wednesday and has continued to rise in early trade. Shares are now up 4.16 at $47.35 on above average volume. The stock has climbed to a 2-week high.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Follow RTT